CENTER FOR DRUG EVALUATION AND RESEARCH
`
`Approval Package for:
`
`APPLICATION NUMBER:
`
`125387Orig1s060
`
`
`
`
`
`Trade Name:
`
` EYLEA
`
`Aflibercept
`
`Regeneron Inc.
`
`August 12, 2019
`
`EYLEA is indicated for the treatment of patients with:
`
` ●
`
` Neovascular (Wet) Age-Related Macular Degeneration
`(AMD)
`● Macular Edema Following Retinal Vein Occlusion
`(RVO)
`● Diabetic Macular Edema (DME)
`● Diabetic Retinopathy (DR)
`
`Generic or Proper
`Name:
`
`Sponsor:
`
`
`
`
`Approval Date:
`
`
`Indication:
`
`
`Novartis Exhibit 2326.001
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`CENTER FOR DRUG EVALUATION AND RESEARCH
`
`125387Orig1s060
`
`CONTENTS
`
`Reviews / Information Included in this NDA Review.
`
`
`
`Approval Letter
`Other Action Letters
`Labeling
`REMS
`Summary Review
`Officer/Employee List
`Office Director Memo
`Cross Discipline Team Leader Review
`Medical Review(s)
`Chemistry Review(s)
`Environmental Assessment
`Pharmacology Review(s)
`Statistical Review(s)
`Microbiology / Virology Review(s)
`Clinical Pharmacology/Biopharmaceutics Review(s)
`Other Reviews
`Risk Assessment and Risk Mitigation Review(s)
`Proprietary Name Review(s)
`Administrative/Correspondence Document(s)
`
`
`X
`X
`X
`
`
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`Novartis Exhibit 2326.002
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`
`
`
`
`
`
`
`
`CENTER FOR DRUG EVALUATION AND
`RESEARCH
`
`
`
`APPLICATION NUMBER:
`125387Orig1s060
`
`
`APPROVAL LETTER
`
`Novartis Exhibit 2326.003
`Regeneron v. Novartis, IPR2021-00816
`
`

`

`(_~"4-~ lffll U.S. FOOD & DRUG
`~L_ 1111 ADMINISTRATION
`, ..
`
`"
`
`BLA 125387 /S-060
`
`Regeneron Pharmaceuticals, Inc.
`Attention: Candace Drumma
`Senior Manager Cmc Regulatory Affairs
`81 Columbia Turnpike, Bldg 85
`Rensselaer, NY 12144
`
`Dear Ms. Drumma:
`
`APPROVAL LETTER
`
`Please refer to your Supplemental Biologics License Application (sBlA} dated and
`received April 12, 2019, and your amendments, submitted under section 351(a) of the
`Public Health Service Act for Eylea (aflibercept) injection, 2 mg/0.05 ml.
`
`We acknowledge receipt of your amendment dated April 12, 2019, which constituted a
`complete response to our October 15, 2018, action letter.
`
`This Prior Approval supplemental biologics license application provides for the addition
`of a new sterile 2 mg/0.05 ml single-dose pre..filJe svdooA i:> S)
`resentatino fn.r:Oiff"l
`afUberc_eo dru_a
`troduci Ibe eES LS UJecLa
`
`t6)
`
`(b)(4)•- - - - - - - - - - - - - - - - '
`
`APPROVAL & LABELING
`
`We have completed our review of th is supplemental application, as amended. It is
`approved, effective on the date of this letter, for use as recommended in the enclosed
`agreed-upon labeling text.
`
`CONTENT OF LABELING
`
`As soon as possible, but no later than 14 days from the date of this letter, submit, via
`the FDA automated drug registration and listing system (eLIST), the content of labeling
`[21 CFR 601.14(b)] in structured product labeling (SPl) format, as described at
`http://www.fda.gov/Forl ndustry/Data Sta nda rds/Stru ctu red Product label ing/defau lt.htm ,
`that is identical to the enclosed labeling (text for the prescribing information) and include
`the labeling changes proposed in any pending "Changes Being Effected" (CBE)
`supplements. Information on submitting SPl files using eLIST may be found in the
`guidance for industry titled SPL Standard for Content of Labeling Technical Qs and As
`at
`http://www.fda.gov/downloads/Dru gs/Guida nceCompl ianceRegu latoryl nformati on/Guida
`ncestuc M072392 .pdf.
`
`U.S. Food & Drug Administration
`Silver Spring, MD 20993
`www.fda.gov
`
`Novartis Exhibit 2326.004
`Regeneron v. Novartis, IPR2021-00816
`
`

`

` ÿ
`

 ÿ
`ÿÿ
`ÿÿ23ÿ ÿ4566ÿ7ÿ8899576ÿ:5ÿ;<76586=ÿ:5676ÿ6765>ÿ?;@95A@?59Bÿ
`ÿÿ69@ÿ45A35>ÿCÿD=9EÿF>Dÿ66ÿ;>D5>ÿ9<;;6F>A6ÿ;;658A5@>9ÿA3Aÿ5>86<Dÿ6765>ÿ
`83>9ÿG@?ÿA359ÿ Eÿ5>86<D5>ÿ;>D5>ÿHI3>9ÿ5>ÿJGG8ADKÿLIJMÿ9<;;6F>A9Eÿ
`G@?ÿ43583ÿNOÿ39ÿ>@Aÿ=Aÿ599<Dÿ>ÿ8A5@>ÿ6AA?Eÿ45A3ÿA3ÿ8@>A>Aÿ@Gÿ6765>ÿ
`PÿINQÿ BLGMRÿ5>ÿSÿT@?DÿG@?FAÿA3Aÿ5>86<D9ÿA3ÿ83>9ÿ;;?@:Dÿ5>ÿA359ÿ
`9<;;6F>A6ÿ;;658A5@>Bÿÿ
`ÿÿUVWXYÿYÿZ++[ZW[ÿUXYWZY[Vÿ\][\ÿ
`ÿÿ<7F5AÿG5>6ÿ;?5>ADÿ8?A@>ÿ>Dÿ5FFD5Aÿ8@>A5>?ÿ6769ÿA3Aÿ?ÿ5D>A586ÿA@ÿA3ÿ
`>86@9Dÿ8?A@>ÿ>Dÿ5FFD5Aÿ8@>A5>?ÿ6769ÿ9<7F5AADÿ@>ÿ^8A@7?ÿ_Eÿ ÿ>Dÿ
`A?Dÿ8?A@>ÿ6765>ÿ9<7F5AADÿ@>ÿ`<6=ÿCEÿ _ÿ9ÿ9@@>ÿ9ÿA3=ÿ?ÿ:5676Eÿ7<Aÿ>@ÿ
`F@?ÿA3>ÿ ÿD=9ÿGA?ÿA3=ÿ?ÿ;?5>ADBÿÿ69ÿ9<7F5AÿA39ÿ6769ÿ68A?@>5866=ÿ
`88@?D5>ÿA@ÿA3ÿ<5D>8ÿG@?ÿ5>D<9A?=ÿabcdefeghÿjkhlmnocbpÿqlrsettecgtÿegÿumkvobcgevÿ
`wcbsnoÿxÿylsngÿaznbsnvkloevnmÿabcflvoÿ{||mevnoecgtÿngfÿjkmnokfÿqlrsettecgtÿ}teghÿ
`ozkÿk~€ÿq|kveevnoecgtÿ‚ƒnpÿ„…†‡ˆÿjkdetecgÿ‰ŠBÿÿN@?ÿDF5>59A?A5:ÿ;<?;@99Eÿ
`D95>AÿA359ÿ9<7F5995@>ÿH‹Œ$ÿU(#)"("Œ(ÿÿ!"%&ÿ‹!"$(ÿU%$"ÿ%"ÿ
`U"$%!"(ÿ\%Ž(&#ÿ1ÿ%))'(ÿ]\ÿ,/‘’“”-•-Kÿÿ;;?@:6ÿ@GÿA359ÿ9<7F5995@>ÿ7=ÿ
`NOÿ59ÿ>@Aÿ?–<5?Dÿ7G@?ÿA3ÿ6765>ÿ59ÿ<9DBÿ
`ÿÿ2359ÿ5>G@?FA5@>ÿ4566ÿ7ÿ5>86<DDÿ5>ÿ=@<?ÿ75@6@589ÿ658>9ÿ;;658A5@>ÿG56Bÿ
`ÿÿ—Gÿ=@<ÿ3:ÿ>=ÿ–<9A5@>9Eÿ866ÿ>D?4ÿ357?EÿQ<6A@?=ÿ<95>99ÿ?@899ÿS>?Eÿ
`AÿL Mÿ _ÿ

ÿC _Bÿ
`ÿÿ
`
`5>8?6=Eÿ
`ÿÿ˜qkkÿn||kgfkfÿkmkvobcgevÿtehgnolbkÿ|nhk™ÿ
`ÿÿšA36>ÿBÿI6@<9Eÿ3BOBÿ
`O5?8A@?ÿ
`O5:595@>ÿ@Gÿ5@A83>@6@=ÿQ:54ÿ>DÿQ9?83ÿ—ÿÿ
`^GG58ÿ@Gÿ5@A83>@6@=ÿ?@D<8A9ÿ
`^GG58ÿ@Gÿ3?F8<A586ÿ›<65A=ÿ
`I>A?ÿG@?ÿO?<ÿJ:6<A5@>ÿ>DÿQ9?83ÿ
`ÿÿÿÿJ>86@9<?L9Mœÿ
`I@>A>Aÿ@Gÿ 765>ÿ
`I?A@>ÿ>DÿI@>A5>?ÿ 765>ÿ
`ÿ
`ÿ
`ÿÿÿÿ !"!#$%$!"ÿ
`!&'(ÿ)!"*ÿ+ÿ,-../ÿ
`0001%'ÿ
`
`Novartis Exhibit 2326.005
`Regeneron v. Novartis, IPR2021-00816
`
`